NCT06332014
Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China
A Phase 4 Single Arm Open Label Study for the Efficacy and Safety of Prolia in Treatment of Male Subjects With Osteoporosis in Mainland China
Amgen·Phase 4·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Osteoporosis
- Drug/Device/Intervention
- Prolia
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Amgen
Timeline & enrollment
- Phase
- Phase 4
- Start date
- Jul 31, 2024
- End date
- Jul 29, 2026
- Enrollment
- 100 participants
Primary outcome
Percent change from baseline in bone mineral density (BMD) of lumbar spine at month 12
Summary
The primary objective of this study is to evaluate the efficacy of Prolia on lumbar spine BMD
 at 12 months.
ICD-10 classifications
Osteoporosis, unspecifiedOther osteoporosisIdiopathic osteoporosisOsteoporosis in diseases classified elsewherePostmenopausal osteoporosis
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06332014
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06332014 through Pure Global AI's free database. This Phase 4 trial is sponsored by Amgen and is currently Not yet recruiting. The study focuses on Osteoporosis. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.